Literature DB >> 18174783

Prompt, aggressive BP lowering in high-risk patients.

Kenneth A Jamerson1, Jan Basile.   

Abstract

Various populations with hypertension have been singled out by current treatment guidelines as requiring more specific treatment. These include patients with stage 2 hypertension, black patients, and patients with coexistent diabetes mellitus and coronary heart disease. Hypertension in these groups is often associated with higher risk of cardiovascular morbidity and mortality. This article reviews current knowledge regarding hypertension in high-risk patient populations, with a particular focus on the importance of prompt, aggressive treatment to lower blood pressure and prevent cardiovascular disease progression. Such treatment includes the early use of multiple-drug therapy with agents that have complementary blood pressure-lowering mechanisms and provide protection from target organ damage. While 2- or 3-drug antihypertensive therapy in these high-risk groups has typically included a diuretic, other combinations of agents may be indicated. Evidence suggests that therapy with a calcium channel blocker and an inhibitor of the renin-angiotensin system is one effective strategy for lowering blood pressure and improving outcomes in these populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174783      PMCID: PMC8110150          DOI: 10.1111/j.1524-6175.2007.08145.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  64 in total

1.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.

Authors:  R O Estacio; B W Jeffers; W R Hiatt; S L Biggerstaff; N Gifford; R W Schrier
Journal:  N Engl J Med       Date:  1998-03-05       Impact factor: 91.245

Review 2.  Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage.

Authors:  J M Flack; G A Mensah; C M Ferrario
Journal:  Curr Med Res Opin       Date:  2000       Impact factor: 2.580

3.  Black-white inequalities in mortality and life expectancy, 1933-1999: implications for healthy people 2010.

Authors:  R S Levine; J E Foster; R E Fullilove; M T Fullilove; N C Briggs; P C Hull; B A Husaini; C H Hennekens
Journal:  Public Health Rep       Date:  2001 Sep-Oct       Impact factor: 2.792

4.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

Review 5.  The management of hypertension in African Americans.

Authors:  Keith C Ferdinand; Annemarie M Armani
Journal:  Crit Pathw Cardiol       Date:  2007-06

6.  The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.

Authors:  Effie L Kuti; William L Baker; C Michael White
Journal:  Curr Med Res Opin       Date:  2007-04-23       Impact factor: 2.580

7.  The effect of antihypertensive drugs and drug combinations on the incidence of new-onset type-2 diabetes mellitus.

Authors:  Thomas A Burke; Miriam C Sturkenboom; Pamela A Ohman-Strickland; Charles E Wentworth; George G Rhoads
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-09       Impact factor: 2.890

8.  Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.

Authors:  Joel M Neutel; Stanley S Franklin; Suzanne Oparil; Amitabha Bhaumik; Agata Ptaszynska; Pablo Lapuerta
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

10.  Ethnic/racial variations in blood pressure awareness, treatment, and control.

Authors:  Thomas Giles; Juan M Aranda; Dong-Churl Suh; In-Sun Choi; Ronald Preblick; Ricardo Rocha; Feride Frech-Tamas
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

View more
  5 in total

1.  Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.

Authors:  J Dingemanse; P Otasevic; K Shakeri-Nejad; E Klainman; B Putnikovic; H Kracker; M S Mueller; R Zimlichman
Journal:  J Hum Hypertens       Date:  2014-09-18       Impact factor: 3.012

Review 2.  No Time to Waste: in Support of Aggressive and Immediate Management of Hypertension.

Authors:  Marat Fudim; Sreekanth Vemulapalli
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 3.  Management of hypertension in patients with coronary artery disease.

Authors:  Wanpen Vongpatanasin
Journal:  Curr Hypertens Rep       Date:  2008-10       Impact factor: 5.369

4.  A critical appraisal of the clinical effectiveness of a fixed combination of valsartan, amlodipine, and hydrochlorothiazide in achieving blood pressure goals.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Integr Blood Press Control       Date:  2011-01-19

5.  Phellodendron and Citrus extracts benefit cardiovascular health in osteoarthritis patients: a double-blind, placebo-controlled pilot study.

Authors:  Julius Oben; Ebangha Enonchong; Shil Kothari; Walter Chambliss; Robert Garrison; Deanne Dolnick
Journal:  Nutr J       Date:  2008-05-20       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.